DAWN — Day One Biopharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00
- $1.24bn
- $878.19m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -17 | -43.8 | -72.8 | -142 | -189 |
Depreciation | |||||
Non-Cash Items | 12 | 30.7 | 21.5 | 25.7 | 32.6 |
Other Non-Cash Items | |||||
Changes in Working Capital | 0.444 | -0.357 | 2.69 | 6.56 | 9.42 |
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Cash from Operating Activities | -4.51 | -13.5 | -48.5 | -110 | -147 |
Capital Expenditures | 0 | -0.092 | 0 | -0.026 | -0.224 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | -8 | -255 | 129 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 0 | -0.092 | -8 | -255 | 128 |
Financing Cash Flow Items | 1 | 0 | 0 | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 30.9 | 30 | 297 | 166 | 164 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 26.4 | 16.4 | 241 | -199 | 146 |